Semaglutide
Glycemic control in type 2 diabetes and weight management; reduces cardiovascular risk
- CAS No.
- 910463-68-2
- Indication Class
- Metabolic / Endocrine
- Patent Expiry
- Off-patent · 2026 (indicative)
- Therapeutic Area
- Endocrine / Metabolism
- Target / Mechanism
- GLP1R
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 3 key intermediates available
- Patent Scope
- China compound patent expires 2026; US / EU to 2031-2033 — wide divergence
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| AEEA-AEEA | 1143516-05-5 | Shared by 2 APIs | |
| AEEA-HCl | 134979-01-4 | Shared by 2 APIs | |
| Boc-AEEA-AEEA | 1069067-08-8 | Shared by 2 APIs |
Listing Logic · Why It's Worth Listing
The most consequential molecule in the GLP-1 class, dual-driven by diabetes and obesity with demand far exceeding capacity; a high-barrier peptide API and our top strategic product.
Endocrine / Metabolism · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
3 key intermediates available; scale-up and cost control manageable
Product Description
Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, was initially used to treat type 2 diabetes, and has rapidly developed into a key drug to deal with obesity, liver disease and other widespread metabolic disorders.
Supply source: Unibest · Semaglutide, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.